🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. LY3454738

    Eli Lilly and Company

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  2. LY4268989

    Eli Lilly and Company

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  3. Larazotide Acetate

    Teva Pharma GmbH

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  4. Leuprolide or goserelin

    NORTHWEST BIOTHERAPEUTICS INC

    Cancer

    phase 2 small molecule completed

    1 trial

  5. Leuprorelin

    Takeda

    Prostatic Neoplasms

    phase 2 small molecule completed

    1 trial

  6. Leuprorelin (GF)

    Takeda

    Uterine Fibroids

    phase 2 small molecule completed

    1 trial

  7. Lucinactant delivered via investigational delivery device

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 small molecule completed

    1 trial

  8. Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion, TEMOZOLOMIDE , LOMUSTINE

    Pari Pharma GmbH

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    phase 2 small molecule active

    1 trial

  9. M1774, M1774, M1774, M1774, M4076, Zejula 100 mg film-coated tablets

    Merck Sharp and Dohme

    Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy

    phase 2 small molecule active

    1 trial

  10. MRx0518

    4D Molecular Therapeutics

    Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial

  11. Midazolam-ratiopharm® 2 mg/ml orale Lösung, JNJ-42756493, JNJ-42756493, Metformin HEXAL 1000 mg Filmtabletten, JNJ-42756493

    Janssen-Cilag International N.V.

    Urothelial cancer

    phase 2 small molecule active

    1 trial

  12. Mirikizumab - Intravenous (IV)

    Eli Lilly and Company

    Colitis, Ulcerative

    phase 2 small molecule active

    1 trial

  13. Mood Management Phone Counseling for Smoking Cessation

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking

    phase 2 other completed

    1 trial

  14. Multivalent recombinant OspA Lyme Borreliosis Vaccine

    Takeda

    Prophylaxis of Lyme Borreliosis

    phase 2 mab completed

    1 trial

  15. MyoScience Tissue Remodeling Device

    Pacira Ireland Limited

    Facial Rhytides

    phase 2 other completed

    1 trial

  16. NALIRIFOX+Adebrelimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  17. NIVOLUMAB

    Disc Medicine

    Peritoneal Mesothelioma

    phase 2 small molecule active

    1 trial

  18. Neoadjuvant Chemotherapy

    Xiangya Hospital of Central South University

    High-Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  19. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  20. ONDANSETRON , APREPITANT , PALONOSETRON, COMBINATIONS, PALONOSETRON , Lagipra, GRANISETRON , DEXAMETHASONE , 0.9% sodium chloride

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 small molecule active

    1 trial

  21. OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  22. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  23. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Tour Hekla

    Unresectable locally advanced or metastatic urothelial cancer

    phase 2 small molecule active

    1 trial

  24. OT-101

    Oncotelic Therapeutics

    COVID-19

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources